Kymera Therapeutic
$77.009876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$77.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$4.30 (-5.29%) Today
$0.00 (0.00%) As of 9:01 PM UTC after-hours
Why Robinhood?
You can buy or sell KYMR and other stocks, options, and ETFs commission-free!
About KYMR
Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA. The listed name for KYMR is Kymera Therapeutics, Inc. Common Stock.
CEO
Nello Mainolfi
Employees
54
Headquarters
Watertown, Massachusetts
Founded
2015
Market Cap
3.10B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
173.20K
High Today
$81.89
Low Today
$75.63
Open Price
$81.89
Volume
89.24K
52 Week High
$91.92
52 Week Low
$25.43
Collections
Analyst Ratings
67%
of 6 ratings
Buy
67%
Hold
33%
Sell
0%
KYMR Earnings
-$0.39
-$0.26
-$0.13
$0.00
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 11, Pre-Market